Anti-Mouse IL-10 [Clone JES5-2A5] — Purified in vivo GOLD™ Functional Grade

Clone JES5-2A5 is a rat monoclonal antibody that serves as a powerful tool for investigating the immunoregulatory functions of interleukin-10 (IL-10) in mouse models. This antibody specifically neutralizes murine IL-10 activity, enabling researchers to study the biological consequences of IL-10 depletion across various experimental contexts.

Primary In Vivo Application

The primary in vivo application of JES5-2A5 is IL-10 neutralization in mouse disease models. By blocking IL-10 function, researchers can examine how this anti-inflammatory cytokine influences immune responses, inflammation, and disease progression in living animals. The antibody has been specifically manufactured for in vivo use with low endotoxin levels (≤ 1.0 EU/mg) and high purity (>95%), making it suitable for preclinical studies.

Specific Research Applications

Inflammatory Disease Models: JES5-2A5 has been used to assess IL-10's role in modulating inflammatory responses. Studies have demonstrated its effectiveness in examining local inflammatory reactions, such as LPS-induced skin inflammation, where IL-10 neutralization results in more severe inflammatory infiltration and tissue damage.

Immuno-oncology Studies: The antibody is utilized in cancer research to understand how IL-10 affects tumor immunity and the tumor microenvironment.

Infectious Disease Research: Researchers employ JES5-2A5 to investigate IL-10's regulatory role during infectious challenges, examining how IL-10 neutralization impacts host defense mechanisms and pathogen clearance.

Technical Characteristics for In Vivo Use

The antibody demonstrates potent neutralizing capacity, with concentrations as low as 0.004 µg/mL achieving 50% inhibition of 1.0 ng/mL mouse IL-10 bioactivity in proliferation assays. This high potency allows for effective in vivo neutralization at reasonable dosing levels. The functional grade formulation ensures minimal endotoxin contamination and is manufactured using protein-free cell culture techniques specifically designed for in vivo applications.

In the literature, several antibodies or proteins are commonly used alongside the JES5-2A5 antibody for detecting or quantifying mouse IL-10. These include:

• JES5-16E3: This antibody is often paired with JES5-2A5 for ELISA, ELISPOT assays, and other related applications. In sandwich ELISAs, JES5-16E3 typically serves as the capture antibody, while biotinylated JES5-2A5 acts as the detection antibody.

• SXC-1: Another antibody used in combination with JES5-2A5 for detecting IL-10. It is sometimes used as a biotinylated detection antibody in ELISA setups.

These antibodies are frequently chosen for their ability to specifically recognize and quantify mouse IL-10 in various experimental settings.

Clone JES5-2A5 is a rat monoclonal antibody widely used in mouse immunology research as a neutralizing and detection reagent specific for mouse interleukin-10 (IL-10), a key immunoregulatory cytokine. The key findings from scientific literature citing clone JES5-2A5 include:

• Central Role in IL-10 Function Studies: JES5-2A5 is consistently cited as a crucial tool for elucidating the immunosuppressive, regulatory, and protective functions of IL-10 in both health and disease models in mice.
• Neutralization and Blocking: It is used to neutralize IL-10 activity both in vivo and in vitro, thereby allowing researchers to dissect the contribution of IL-10 to specific immune outcomes such as inflammation, autoimmunity, tissue protection, and tumor immunity.
• Assay Applications: JES5-2A5 serves as a capture antibody in ELISA and ELISPOT, as well as in flow cytometry, immunohistochemistry, and Western blotting to detect IL-10, enabling quantification and localization in mouse tissues and cell types.
• Broad Use in Disease Models: Studies using JES5-2A5 have demonstrated that:
  • Neutralization or genetic ablation of IL-10 exacerbates immune-mediated diseases like colitis and enhances anti-tumor responses, underscoring IL-10’s role in limiting immune pathology and controlling pro-inflammatory cells.
  • IL-10 production from various immune cells (B cells, monocytes/macrophages, Th2 cells) is essential for restraining excessive inflammation and mediating tissue protection in infections, autoimmunity, and cancer.
• Specific Experimental Contexts:
  • Used to demonstrate that B cell-derived IL-10 governs pro-inflammatory activity of peripheral myeloid cells and microglia, highlighting its regulatory impact beyond classical T cell immunity.
  • Essential as a capture antibody in studies quantifying IL-10 induction by microbial metabolites, cell-cell interactions, or cytokine milieu in both primary cell cultures and in vivo systems.

Summary Table: Key Uses of Clone JES5-2A5 in Research

In conclusion, citations of clone JES5-2A5 uniformly underscore its pivotal utility in clarifying the roles of IL-10 in immune regulation, disease limitation, and experimental dissection of immunosuppressive pathways in mice.

Dosing regimens of clone JES5-2A5, a rat anti-mouse IL-10 neutralizing antibody, vary considerably across mouse models and experimental settings, with doses and administration routes tailored to the specific disease model, mouse strain, and research objective.

Key contextual details:

• Route and Frequency: JES5-2A5 is most frequently administered either intraperitoneally (i.p.), intravenously (i.v.), or intratumorally, depending on the study design.

• Reported Dosages:

  • In cancer immunotherapy models, 150 µg per dose was administered intratumorally every three days, up to 6 doses beginning day 5 post-tumor induction.
  • Some studies use dosing regimens ranging between 100–250 µg per injection, often given on alternate days or weekly, especially in inflammatory or autoimmune disease models (inferred from supplier and literature dosing examples cited for neutralization applications).
  • For in vitro neutralization, the antibody inhibits 50% of the biological effect of 1 ng/mL mouse IL-10 at 0.004 µg/mL JES5-2A5.

• Variation Factors:

  • Mouse strain: Immunocompetence and background influence dosing (e.g., C57BL/6 vs BALB/c may metabolize antibody differently).
  • Disease model: Autoimmune, infection, or cancer models may use higher or more frequent dosing regimens due to differences in IL-10 production and immune activity.
  • Research goal: Studies aiming for complete IL-10 neutralization typically use higher and more frequent dosing than those aiming for partial blockade.

• Adjustment Guidance: Reagent suppliers and protocol references emphasize that "antibody reactivity and working conditions may vary between species", and regimens should be tailored to experimental needs.

Essential Points for Researchers:

• There is not a universal dosing regimen for JES5-2A5; doses should be defined based on pilot studies and literature precedent for the specific mouse model and target indication.
• It is critical to consult supplier datasheets and published protocols for starting dose recommendations and adjust empirically.

Summary Table: JES5-2A5 Common Dosing Regimens in Mouse Models

If planning an experiment, consider running a pilot and reviewing closely related published methods in the same model for appropriate dosing.